※ 引述《bons2 (就是現在)》之銘言：
: ※ 引述《Dimitre (迪米崔)》之銘言：
: : 1.原文連結：
: : ※過長無法點擊者必須縮網址
: : https://reurl.cc/GVGreD
: : 2.原文內容：
: : Moderna’s closely watched early-stage human trial for a coronavirus vacci
ne
: : produced Covid-19 antibodies in all 45 participants, the biotech company
: : announced Monday.
: : Each participant was assigned to receive a 25 microgram, 100 mcg or 250 mc
g
: : dose, with 15 people in each dose group. Study participants received two
: : doses of the potential vaccine via intramuscular injection in the upper ar
m
: : approximately 28 days apart. Data on a second dose was not available for t
he
: : 250 mcg group, the company said.
: : At day 43, or two weeks following the second dose, levels of binding
: : antibodies in the 25 mcg group were at the levels generally seen in blood
: : samples from people who recovered from the disease, the company said.
: : Antibodies in the 100 mcg had antibodies that “significantly exceeded lev
el
: : ” in recovered patients.
: : The vaccine also produced neutralizing antibodies against Covid-19 in at
: : least eight participants, the company said. Four participants were assigne
d
: : to receive a 25 microgram dose, while the other four received 100 mcg. Lev
el
: : of neutralizing antibodies were at or above levels in blood samples, the
: : company said. Data on neutralizing antibodies for the other participants w
er
: : not yet available, Moderna said.
: : “These interim Phase 1 data, while early, demonstrate that vaccination wi
th
: : mRNA-1273 elicits an immune response of the magnitude caused by natural
: : infection starting with a dose as low as 25 μg,” Tal Zaks, the chief
: : medical officer at Moderna, said in s statement.
: : “When combined with the success in preventing viral replication in the lu
ng
: : of a pre-clinical challenge model at a dose that elicited similar levels o
f
: : neutralizing antibodies, these data substantiate our belief that mRNA-1273
: : has the potential to prevent COVID-19 disease and advance our ability to
: : select a dose for pivotal trials,” Zaks added.
: : There are formally approved treatments for Covid-19, which has killed at
: : least 315,225 and sickened 4.7 million people worldwide since emerging fro
m
: : the Chinese city of Wuhan more than 4 months ago, according to data compil
ed
: : by Johns Hopkins University.
: : Moderna has been fast-tracking work with the National Institutes of Health
,
: : an agency within the Department of Health and Human Services, to develop a
: : vaccine.
: : The company said the vaccine was generally safe and well tolerated.
: : The potential vaccine by Moderna contains genetic material called messenge
r
: : RNA, or mRNA, that was produced in a lab. The mRNA is a genetic code that
: : tells cells what to build — in this case, an antigen that may induce an
: : immune response for the virus.
: : The phase 1 trial took place at the Kaiser Permanente Washington Health
: : Research Institute in Seattle, Washington. It tested the vaccine on 45 mal
es
: : and non-pregnant females between the ages of 18 and 55.
: : 3.心得/評論：
: : ※必需填寫滿20字
: : 粗略翻譯
: : Moderna公布早期臨床試驗報告
: : 45個受試者分為25mg ,100mcg, 250mcg不等劑量疫苗的組別
: : 每組各15個
: : 所有受試者除了250mcg的以外都隔一個月施打兩劑
: : 在研究的第43天 25mcg的受試者體內的抗體量跟得過COVID-19又痊癒的人一樣
: : 100mcg的受試者體內抗體量遠多於痊癒的人
: : 少數受試者甚至有能直接對抗COVID病毒的抗體
: : Moderna目前盤前大漲25% 小道直接噴到600點
: : 明天台股又要噴出了嗎
: : 國光生 高端疫苗又怎麼走?
: :